Maerz, Winfried and Schmidt, Nina and Haack, Ira An and Dressel, Alexander and Grammer, Tanja B. and Kleber, Marcus E. and Baessler, Andrea and Beil, F. Ulrich and Gouni-Berthold, Ioanna and Julius, Ulrich and Kassner, Ursula and Katzmann, Julius L. and Klose, Gerald and Koenig, Christel and Koenig, Wolfgang and Koschker, Ann-Cathrin and Laufs, Ulrich and Merkel, Martin and Otte, Britta and Parhofer, Klaus G. and Hengstenberg, Wibke and Schunkert, Heribert and Stach-Jablonski, Ksenija and Steinhagen-Thiessen, Elisabeth and Olivier, Christoph B. and Hahmann, Harry and Krzossok, Stefan and Vogt, Anja and Mueller-Wieland, Dirk and Schatz, Ulrike (2023) The German CaRe high registry for familial hypercholesterolemia- Sex differences, treatment strategies, and target value attainment. ATHEROSCLEROSIS PLUS, 53. pp. 6-15. ISSN 2667-0909, 2667-0895
Full text not available from this repository. (Request a copy)Abstract
Background and aims: Familial hypercholesterolemia (FH) is among the most common genetic disorders in primary care. However, only 15% or less of patients are diagnosed, and few achieve the goals for low -density lipoprotein cholesterol (LDL-C). In this analysis of the German Cascade Screening and Registry for High Cholesterol (CaRe High), we examined the status of lipid management, treatment strategies, and LDL-C goal attainment according to the ESC/EAS dyslipidemia guidelines.Methods: We evaluated consolidated datasets from 1501 FH patients diagnosed clinically and seen either by lipid specialists or general practitioners and internists. We conducted a questionnaire survey of both the recruiting physicians and patients.Results: Among the 1501 patients, 86% regularly received lipid-lowering drugs. LDL-C goals were ach-ieved by 26% and 10% of patients with atherosclerotic cardiovascular disease (ASCVD) according to the 2016 and 2019 ESC/EAS dyslipidemia guidelines, respectively. High intensity lipid-lowering was administered more often in men than in women, in patients with ASCVD, at higher LDL-C and in patients with a genetic diagnosis of FH.Conclusions: FH is under-treated in Germany compared to guideline recommendations. Male gender, genetic proof of FH, treatment by a specialist, and presence of ASCVD appear to be associated with increased treatment intensity. Achieving the LDL-C goals of the 2019 ESC/EAS dyslipidemia guidelines remains challenging if pre-treatment LDL-C is very high.& COPY; 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MANAGEMENT; CHOLESTEROL; MUTATIONS; GUIDANCE; THERAPY; GENES; Familial hypercholesterolemia; Cascade screening; Patient registry; Cardiovascular risk; Treatment; Adherence; Low-density lipoproteins |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Jan 2024 12:41 |
| Last Modified: | 30 Jan 2024 12:41 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60893 |
Actions (login required)
 |
View Item |
